University of Cambridge launches Bio-Medical Cloud service


University research project uses converged HPC and data analytics

The University of Cambridge has announced a Bio-Medical Cloud service that combines HPC and data analytics to help those without technological expertise to take advantage of powerful computer technologies to gain insights, whether that's for patient care or further research into medical conditions.

The University of Cambridge is predicting it will revolutionise the way its researchers process and model data, offering flexibility and ease of use compared to previous methods of analysing scientific data.

The institution partnered with Dell EMC and Intel to design and implement the system, which uses OpenStack combined with Dell's HPC hardware, including the Dell PowerEdge C6320, the Dell PowerEdge R630 and the Dell PowerVault MD3460 servers.

“There’s a revolution occurring across scientific, technical and medical research disciplines, generating demand for platforms which can handle a large user-base of computational techniques and data intensive science,” said Bart Mellenbergh, director, HPC Dell EMC EMEA.

“Dell EMC offers HPC capabilities, accelerated by the latest hardware technology, to handle the excessive demands of large-scale data modelling whilst also providing additional flexibility and accessibility through open source cloud computing.”

The set-up also makes use of Intel's latest generation processors and NvRAM technologies with Ethernet networking, which accelerates the process of analysing data to serve up a more agile solution to researchers.

“The Cambridge Bio-Medical Cloud heralds a transformation in the manner in which Research Computing Services are being delivered,” said Dr Paul Calleja, director, Research Computing at the UIS, University of Cambridge added.

"With the assistance of superior hardware and core technologies, this new platform will radically democratise access to large-scale compute and data resources and ultimately contribute to significant advancements in the treatment discovery process.”

Read more about:

Sign up for our free newsletter